King Altace sNDA Submitted For Five Indications; 4th Quarter Sales Grew 46%
Executive Summary
King submitted an Altace (ramipril) sNDA Jan. 18 for the significant reduction of mortality, myocardial infarction, stroke, revascularization procedures and heart failure in patients at risk for such events.
You may also be interested in...
Comparative Hypertensive Trials Preferred Endpoint Is Systolic BP, Cmte Says
The primary efficacy endpoint in comparative antihypertensive trials should shift from diastolic blood pressure measured at trough levels to systolic blood pressure at trough, FDA's Cardiovascular & Renal Drugs Advisory Committee member Steven Nissen, MD, suggested July 18
Comparative Hypertensive Trials Preferred Endpoint Is Systolic BP, Cmte Says
The primary efficacy endpoint in comparative antihypertensive trials should shift from diastolic blood pressure measured at trough levels to systolic blood pressure at trough, FDA's Cardiovascular & Renal Drugs Advisory Committee member Steven Nissen, MD, suggested July 18
Altace Will Gain 1,000 Wyeth Reps Through Copromotion Deal
Wyeth-Ayerst is allocating approximately 1,000 sales reps to promote King's Altace in the U.S. and Puerto Rico, under a copromotion agreement announced June 23.